The infusion pump market is projected to expand at a Compound Annual Growth Rate (CAGR) of 5.5%, from USD 11.1 billion in 2025 to USD 14.5 billion in 2030.
Infusion pumps serve a critical function within the medical field, facilitating the controlled delivery of fluids, including medications and nutrients, into patients' bodies. These devices are integral across various healthcare environments, from hospitals and nursing homes to homecare settings. Operated by trained personnel, infusion pumps utilize a precise software interface to program fluid delivery rates and durations, enabling the administration of small volumes at automated intervals. This capability enhances accuracy and reliability in medical treatments. Substances administered via infusion pumps include vital medications such as insulin, hormones, antibiotics, chemotherapy drugs, and pain relievers.
A diverse range of infusion pump types addresses specific clinical requirements. These include large-volume pumps, patient-controlled analgesia (PCA) pumps, elastomeric pumps, syringe pumps, enteral pumps, and insulin pumps. While some pumps are stationary and primarily bedside-based, others, known as ambulatory infusion pumps, are designed for portability or are wearable, offering enhanced operational flexibility.
Infusion pumps can be powered either electrically or mechanically, with operational mechanisms varying by type. For instance, syringe pumps employ a movable piston to control fluid delivery from a syringe reservoir. Elastomeric pumps utilize a stretchable balloon reservoir, where pressure from the elastic walls propels fluid. Peristaltic pumps use a series of rollers to compress flexible tubing, moving fluid forward. Multi-channel pumps, conversely, enable the simultaneous delivery of fluids from multiple reservoirs at distinct rates. The precision and versatility of infusion pumps render them indispensable instruments in modern healthcare delivery.
Rise in Healthcare Expenditure
The World Health Organization (WHO) highlights a significant concern regarding non-communicable diseases (NCDs). Projections indicate that if current trends persist, chronic conditions such as cardiovascular diseases, cancer, diabetes, and respiratory illnesses will account for 86% of the 90 million annual deaths by approximately 2050. The prevalence of many chronic diseases is linked to common risk behaviors, including tobacco use and exposure to secondhand smoke, inadequate nutrition, physical inactivity, and excessive alcohol consumption. In response to this increasing prevalence, governments globally are committing greater financial resources to healthcare.
In the United States, health spending increased by 4.1% in 2023, reaching $4.8 trillion, or $14,424 per capita. While this growth rate is lower than the 10.3% observed in 2020, it underscores the substantial financial commitment to managing chronic diseases. Across European Union Member States, Germany reported the highest current healthcare expenditure, reaching EUR 487 billion in 2022, followed by France at EUR 305 billion, Italy at EUR 169 billion, and Spain at EUR 130 billion.
Healthcare expenditures in Germany and France represented 12.8% and 12.2% of their respective Gross Domestic Product (GDP). These figures emphasize the growing financial commitment by governments to address healthcare challenges posed by the increasing burden of chronic conditions and evolving lifestyles. Such trends in healthcare spending directly influence the broader healthcare market, impacting the demand for medical technologies like infusion pumps. The evolving landscape necessitates adaptive healthcare systems capable of effectively managing the rising incidence of chronic diseases.
Growing Geriatric Population
Global demographic shifts are profoundly reshaping market dynamics. In the Asia-Pacific (APAC) region, the population aged 60 or older constituted approximately 12.4% in 2016. Projections indicate a substantial increase, exceeding a quarter of the population, or 1.3 billion people, by 2050. This demographic transition highlights escalating healthcare demands, particularly in East and North Asia, which includes Japan and the Republic of Korea, where over a third of the population is expected to be aged 60 or older by 2050.
Similarly, the European Union (EU) is experiencing a direct correlation between its aging population and the demand for infusion pumps. The population aged 65 and older in the EU-27 is projected to surge from 91.4 million in 2023 to 129.8 million by 2050. Within this timeframe, the 75-84 year-old segment is anticipated to grow by 56.1%, while the 65-74 year-old group is expected to increase by 16.6%.
In the United States, the older population experienced a significant growth rate of 38.6% from 2010 to 2020, rising from 40.3 million to 55.8 million. This expansion is more than double the rate of the preceding decade, indicating a substantial demographic shift. The global acceleration in the growth of the older population directly underscores the increasing importance of healthcare technologies, including infusion pumps, as indispensable components for addressing the evolving healthcare requirements associated with an aging global populace.
Product Recalls
Infusion pumps, as sophisticated medical devices, inherently carry risks of malfunction or software defects. These issues can lead to product recalls, resulting in significant financial and reputational damage for manufacturers. A recent example occurred in September 2023, when Becton Dickinson (BD)/CareFusion 303 initiated a recall of Alaris Infusion Pumps due to compatibility concerns with Cardinal Health Monoject Syringes. The Alaris infusion pump, a modular system, is designed for the precise delivery of medications or other fluids.
Notably, the syringe and PCA pump modules are validated exclusively for use with specific syringes. This highlights the critical necessity of ensuring precise compatibility to mitigate adverse incidents and uphold the integrity of healthcare delivery systems.
By Type, the Infusion Pump Market Is Segmented into Insulin Pump, PCA Pump, Enteral Pump
The infusion pump market is segmented by type to address distinct medical requirements. Patient-controlled analgesia (PCA) pumps provide patients with autonomy in managing pain medication. Insulin pumps are widely adopted in home settings for controlled diabetes management. Enteral pumps are specifically designed for direct administration of liquid nutrients and medications to a patient's digestive tract.
North America Is Anticipated to Hold a Significant Share of the Infusion Pump Market
North America is positioned to command a substantial share within the Infusion Pump Market. Recent data from the American Hospital Association indicates a notable increase in the total count of U.S. hospitals, rising from 6,093 in 2022 to 6,120 in 2024. The scale of medical activity is underscored by cumulative hospital admissions, reaching 34,113,745 in 2024, compared to 33,356,853 admissions recorded in 2022 (projections based on AFA). In Canada, health spending is projected to reach $344 billion in 2024, or $8,843 per Canadian (projections based on CIHI).
Anticipated growth in spending is driven by the return of deferred care post-pandemic, contributing to an increase in healthcare services. Demographic factors, including population aging and growth, further fuel spending expansion, creating a favorable environment for overall healthcare facilities and the adoption of infusion pumps.
February 2026: Modular Medical announced production validation milestones for its Pivot tubeless patch pump system, progressing toward commercial launch and expanding insulin infusion pump technologies targeting simplified diabetes therapy.
October 2025: IRadimed Corporation began initial deployments of the MRidium 3870 infusion pump system to selected healthcare facilities, initiating commercialization of its MRI-safe infusion technology for hospital environments.
August 2025: Terumo Corporation launched Terufusion Advanced Infusion Systems in India, integrating smart syringe pumps, volumetric infusion pumps, and monitoring software to improve drug-delivery accuracy, ICU safety, and digital workflow management.
April 2025: ICU Medical announced U.S. FDA 510(k) clearance for the Plum Solo precision IV pump and updated Plum Duo pump and LifeShield safety software, launching a new category of precision infusion pumps.
This global infusion pump market report provides strategic and executive-level insights, complemented by data-driven analysis and forecasts of the industry landscape. The report is regularly updated to offer decision-makers actionable intelligence regarding current market trends, emerging opportunities, and competitive dynamics. It also explores the demand for various infusion pump types, including insulin pumps, PCA pumps, enteral pumps, and others, analyzing their demand across geographies. The report further scrutinizes the latest technological advancements, key government policies, regulations, and macroeconomic factors to present a comprehensive market view.
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 11.1 billion |
| Total Market Size in 2030 | USD 14.5 billion |
| Forecast Unit | Billion |
| Growth Rate | 5.5% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Mechanism, Application, Region |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|